GCP
XFOR icon

GSA Capital Partners’s X4 Pharmaceuticals XFOR Stock Holding History

GSA Capital Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132,724
Closed -$252K – 2162
2025
Q2 		$252K Buy
+132,724
New +$543K 0.02% 1375
2025
Q1 		– Sell
-42,455
Closed -$934K – 2134
2024
Q4 		$934K Buy
42,455
+25,532
+151% +$407K 0.07% 452
2024
Q3 		$340K Buy
+16,923
New +$353K 0.03% 1163
2024
Q2 		– Sell
-10,701
Closed -$446K – 2080
2024
Q1 		$446K Sell
10,701
-20,805
-66% -$579K 0.04% 955
2023
Q4 		$793K Buy
31,506
+10,786
+52% +$262K 0.07% 516
2023
Q3 		$678K Buy
+20,720
New +$904K 0.06% 609

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSA Capital Partners's XFOR Position: Q3 2025 in Review

GSA Capital Partners sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 132,724 shares — an estimated $252K sold.

GSA Capital Partners first reported a position in XFOR in Q3 2023 and held it in 6 quarters. The position peaked at $934K in Q4 2024. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • GSA Capital Partners reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 132,724 X4 Pharmaceuticals shares in Q3 2025, an estimated $252K.
  • GSA Capital Partners first reported a position in X4 Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • GSA Capital Partners's X4 Pharmaceuticals position peaked at $934K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.